Neisseria meningitidis factor H binding protein
Highest phase reached
Approved
Drug type
Vaccine component
First approval year
2013
- First approval year
- 2013
- Listing at source
- Listed
- Highest phase reached
- Approved
- Drug type
- Vaccine component
- Drug name
- Neisseria meningitidis factor H binding protein
- neisseria meningitidis factor h binding protein component of bexsero
- Neisseria meningitidis factor h binding protein component of bexsero
- neisseria meningitidis group b recombinant lp2086 a05 protein variant antigen component of penbraya
- Neisseria meningitidis group b recombinant lp2086 a05 protein variant antigen component of penbraya
- neisseria meningitidis group b recombinant lp2086 b01 protein variant antigen component of penbraya
- Neisseria meningitidis group b recombinant lp2086 b01 protein variant antigen component of penbraya
- trumenba
- Trumenba
- Meningococcal Group B vaccine (Trumenba®)
- meningococcal group b vaccine trumenba
- neisseria meningitidis factor h binding protein
- Neisseria meningitidis factor h binding protein
- neisseria meningitidis group b recombinant lp2086 a05 protein variant antigen
- Neisseria meningitidis group b recombinant lp2086 a05 protein variant antigen
- neisseria meningitidis group b recombinant lp2086 b01 protein variant antigen
- Neisseria meningitidis group b recombinant lp2086 b01 protein variant antigen
- Trumenba
- Trumenba®
- ChEMBL ID
- CHEMBL6068499
- Patents
- 0
- Designations
- 1
- First in class
- No
- Fast track
- No
- Breakthrough designation
- Yes
- Orphan designation
- No
- Priority review
- No
- Orphan exclusivity
- No
- Accelerated approval
- No
Mechanisms of action
- Mechanism
- Factor H binding protein vaccine antigen
- Action type
- VACCINE_ANTIGEN
- Target
- Factor H binding protein
- Protein identifier
- Q9JXV4
Open Targets mechanisms
- Mechanism
- Factor H binding protein vaccine antigen
- Action type
- VACCINE ANTIGEN
- Target
- Factor H binding protein
- Condition
- Meningitis
- Highest recorded phase
- 4
- Condition identifier
- EFO:0000584
- Subject identifier
- D008581
- Condition
- Vaccination
- Highest recorded phase
- 4
- Condition identifier
- EFO:0004292
- Subject identifier
- D014611
- Condition
- Meningitis, Meningococcal
- Highest recorded phase
- 4
- Condition identifier
- EFO:1001040
- Subject identifier
- D008585
- Condition identifier
- EFO_0000584
- Condition identifier
- EFO_0004249
- Condition identifier
- EFO_1001040
- Condition identifier
- MONDO_0004796
- Highest recorded phase
- 4
- Condition identifier
- MONDO_0005373
- Highest recorded phase
- 4
- Condition identifier
- MONDO_0021108
- Condition identifier
- MONDO_0021108
- Highest recorded phase
- 4
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Natural product
- No
Related records
Trials (18)
- A Study to Learn About How Trumenba Vaccine Shots Work Against Gonorrhea Infection in Teenagers and Young Adults in the United States.
- Efficacy of Immunization With 4C-MenB in Preventing Experimental Urethral Infection With Neisseria Gonorrhoeae
- Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine in Infants and Toddlers When Administered Concomitantly With Routine Pediatric Vaccines in the United Kingdom
- Investigating the Immunogenicity of a U.S.-Licensed Meningococcal Serogroup B Vaccine (Trumenba)
- MenABCWY Noninferiority Study in Healthy Participants ≥10 to <26 Years of Age
- MenB-FHbp or MenACWY-TT/MenB-FHbp Vaccine in MenB-4C Primed Young Adults
- Mucosal Immunity Against Neisseria Gonorrhoeae After 4CMenB Vaccination
- Research Trial Assessing the Immunogenicity and Safety of Three Meningococcal B Vaccine Strategies Among Patients With Asplenia.
- Safety and Efficacy Study of Meningococcal Group B Vaccine rMenB+OMV NZ (Bexsero) to Prevent Gonococcal Infection
- Safety and Immunogenicity of an Investigational Pentavalent Meningococcal ABCYW Vaccine Against Meningococcal Disease in Children, Toddlers, and Infants
- Safety and Immunogenicity of GlaxoSmithKline Biologicals Meningococcal Group B Vaccine When Administered Concomitantly With GlaxoSmithKline Biologicals MenACWY Conjugate Vaccine to Healthy Infants
- Safety and Immunogenicity of GSK Meningococcal Group B Vaccine and 13-valent Pneumococcal Vaccine Administered Concomitantly With Routine Infant Vaccines to Healthy Infants
- Study of a Novel Multicomponent Meningococcal Group B Vaccine When Given Alone or With Other Licensed Vaccines in Adults, Adolescents, Toddlers and Infants
- Study of an Investigational Pentavalent Meningococcal ABCYW Vaccine in Adults and Adolescents
- Study to Assess Gonorrhoeae Immune Responses Induced by a N. Meningitidis Vaccine
- Study to Assess the Safety and Immunogenicity of GSK Meningococcal Group B Vaccine When Administered Concomitantly With GSK Meningococcal MenACWY Conjugate Vaccine in Healthy Subjects of 16-18 Years of Age
- Study to Evaluate the Immune Response After a Booster Dose of a Quadrivalent Meningococcal (MenACYW) Conjugate Vaccine When Administered Alone or Concomitantly With a Licensed Meningococcal Serogroup B Vaccine, in Participants Who Received Primary Quadrivalent Meningococcal Conjugate Vaccine (MCV4)
- Trial to Describe the Safety, Tolerability, and Immunogenicity of Trumenba When Administered to Immunocompromised Participants ≥10 Years of Age
Approved for (2)
- Infectious meningitis
- Meningococcal meningitis
Other linked conditions (2)
- Meningitis
- Meningococcal infection